AstraZeneca’s Lisa Anson appointed president of ABPI
Lisa Anson, current president of AstraZeneca UK & Ireland, has been appointed to the position of president of ABPI. Lisa Anson has been a member of the board at the ABPI since January 2012. During this time, she led the implementation of the Pharmaceutical Pricing Regulation Scheme. Lisa Anson will take up the role formally from the end of April, 2017, taking over from current APBI President John Kearney, General Manager at Amgen.
Prior to joining AstraZeneca, she worked as a consultant to KPMG and received an MBA from INSEAD in France, and a first-class degree in Natural Sciences from Cambridge.
Lisa Anson commented upon her appointment by saying, “I am honoured and delighted to be elected as the next President of the ABPI to build on John Kearney’s leadership. During my term as President, our industry will face crucial issues including the UK’s departure from the European Union, ensuring biopharmaceuticals are central to the UK industrial strategy and leveraging a golden period of innovation in new medicines to ensure UK patients benefit. The ABPI is at the frontline of protecting and nurturing our relationship with government and the NHS, which will be vital to navigate these important issues.”
ABPI’s Chief Executive, Mike Thompson, said: “The unanimous decision by the ABPI Board to elect Lisa Anson as President shows the esteem in which she is held. As a high profile President of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry’s most challenging era to date. Lisa will play a leading role as we negotiate the future of our industry outside of the European Union and as we work with government to build an industrial strategy with life-sciences at its heart. Speaking on behalf of the Board and all staff at the ABPI, we very much look forward to working with Lisa.”